Aleor Dermaceuticals receives USFDA Final Approval for Testosterone Topical Solution USP, 30 mg per pump actuation

Alembic Pharmaceuticals Limited (Alembic) today announced that its joint venture Aleor Dermaceuticals Limited (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Testosterone Topical Solution USP, 30 mg per pump actuation. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Axiron Topical Solution, 30 mg per pump actuation, of Eli Lilly and Company (Lilly). Testosterone Topical Solution USP, 30 mg per pump actuation is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) and Hypogonadotropic hypoqonadisrn (congenital or acquired).

Testosterone Topical Solution USP, 30 mg per pump actuation has an estimated market size of US$ 21 million for twelve months ending March 2021 according to IQVIA.

Alembic has a cumulative total of 145 ANDA approvals (127 final approvals and 18 tentative approvals) from USFDA.

Shares of ALEMBIC PHARMACEUTICALS LTD. was last trading in BSE at Rs.1004.55 as compared to the previous close of Rs. 994.55. The total number of shares traded during the day was 12613 in over 1138 trades.

The stock hit an intraday high of Rs. 1005 and intraday low of 987.75. The net turnover during the day was Rs. 12569498.

Source : Equity Bulls

Keywords